Clinical trial
Multicenter Open-label, Randomized, Dose-finding, Parallel-group, Safety and Efficacy Trial of Subcutaneous Administration of Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
NCT00294918 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter Open-label, Randomized, Dose-finding, Parallel-group, Safety and Efficacy Trial of Subcutaneous Administration of Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
- Lead sponsor
- EMD Serono
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2001
- Completion date
- February 28, 2003
- Enrollment
- 142 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
human immunodeficiency virus infections, human immunodeficiency virus-associated adipose redistribution syndrome (hars)